Biologically Active Small Molecules

A glucocorticoid steroid that activates the glucorcorticoid receptor with an EC₅₀ value of 12.4 nM reduces inflammation and has utility in inflammatory diseases, like asthma and inflammatory bowel disease may be abused by athletes.

A glucocorticoid steroid that activates the glucorcorticoid receptor with an EC₅₀ value of 12.4 nM reduces inflammation and has utility in inflammatory diseases, like asthma and inflammatory bowel disease may be abused by athletes.

A cardiotonic steroid that inhibits theNa+/K+-ATPase transporter (Kds = 42, 45, and 40 nM for the &alpha1, &alpha2, and &alpha3 subunits, respectively) inhibits SRC-1 and SRC-3 at doses as low as 5 nM, promotes the degradation of SRC-3 protein,

A cardiotonic steroid that inhibits theNa+/K+-ATPase transporter (Kds = 42, 45, and 40 nM for the &alpha1, &alpha2, and &alpha3 subunits, respectively) inhibits SRC-1 and SRC-3 at doses as low as 5 nM, promotes the degradation of SRC-3 protein,

A cardiotonic steroid that inhibits theNa+/K+-ATPase transporter (Kds = 42, 45, and 40 nM for the &alpha1, &alpha2, and &alpha3 subunits, respectively) inhibits SRC-1 and SRC-3 at doses as low as 5 nM, promotes the degradation of SRC-3 protein,

A cardiotonic steroid that inhibits theNa+/K+-ATPase transporter (Kds = 42, 45, and 40 nM for the &alpha1, &alpha2, and &alpha3 subunits, respectively) inhibits SRC-1 and SRC-3 at doses as low as 5 nM, promotes the degradation of SRC-3 protein,

A biguanide that exhibits antihyperglycemic activity by increasing glucose utilization and inhibiting hepatic gluconeogenesis inhibits the mitochondrial respiratory complex I and the mitochondrial ATP synthase disrupts the unfolded protein

A biguanide that exhibits antihyperglycemic activity by increasing glucose utilization and inhibiting hepatic gluconeogenesis inhibits the mitochondrial respiratory complex I and the mitochondrial ATP synthase disrupts the unfolded protein

A biguanide that exhibits antihyperglycemic activity by increasing glucose utilization and inhibiting hepatic gluconeogenesis inhibits the mitochondrial respiratory complex I and the mitochondrial ATP synthase disrupts the unfolded protein

A non-specific &beta-adrenergic blocker with affinity for both &beta1 and &beta2-adrenergic receptors acts as a potent &beta-adrenoceptor antagonist with partial agonist activity metabolized by CYP2D6, CYP1A2, and CYP2C19.

A non-specific &beta-adrenergic blocker with affinity for both &beta1 and &beta2-adrenergic receptors acts as a potent &beta-adrenoceptor antagonist with partial agonist activity metabolized by CYP2D6, CYP1A2, and CYP2C19.

A non-specific &beta-adrenergic blocker with affinity for both &beta1 and &beta2-adrenergic receptors acts as a potent &beta-adrenoceptor antagonist with partial agonist activity metabolized by CYP2D6, CYP1A2, and CYP2C19.